Roles of Prophylactic Subcutaneous Drain in Preventing Surgical Site Infection in Surgical Wound After Abdominal Surgery

Sponsor
Queen Savang Vadhana Memorial Hospital, Thailand (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06063629
Collaborator
(none)
80
2
16.1

Study Details

Study Description

Brief Summary

Surgical site infections (SSI) pose a common challenge in the field of surgery. Current evidence and literature do not provide clear consensus whether the use of subcutaneous drainage will help reduce the incidence of SSI in patients who underwent abdominal surgery, especially in wounds that are categorized as contaminated (class 3) or dirty/infected (class 4).

The objective of this clinical study is to compare the rate of surgical site infection in contaminated and dirty/infected surgical wounds among patients whose wounds are inserted with subcutaneous drainage and patients who are not inserted with subcutaneous drainage.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Subcutaneous drain
  • Procedure: No drain
N/A

Detailed Description

This study is a randomized, controlled and open study, where participants who undergo abdominal surgery will be randomly allocated into two groups: (i) patients whose wounds are inserted with subcutaneous negative pressure drain and (ii) patients whose wounds are not inserted with subcutaneous negative pressure drain.

The participants in this study will know the details about the presence of their drain placement after the operation. If the patient was assigned to the drain group, the drain will be placed for three days. The primary outcome of this study is the occurrence of SSI, which will be tracked up to 30 days post-operation. The patient in both groups will also be evaluated by the surgeons at day 3, 5, 7, 14 and 30 post-operation for signs and complications of SSI. In situation where the patients are discharged prior to the date of evaluation, the patients will be scheduled for evaluation during the follow-up visits.

If SSI is detected in the drain group prior to removal, the drain will be removed and the patient will be treated with wet dressing combined with antibiotics. Complications of SSI will also be noted. Patient's data on demographic, medical history, clinical presentation, details of operation, and other laboratory findings will also be collected to investigate for risk factors for development of SSI between each group.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
80 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Roles of Prophylactic Subcutaneous Drain in Preventing Surgical Site Infection in Abdominal Surgery Wound Class III and IV
Anticipated Study Start Date :
Oct 1, 2023
Anticipated Primary Completion Date :
Sep 1, 2024
Anticipated Study Completion Date :
Feb 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: Subcutaneous drain

The drain will be inserted into subcutaneous layer of the surgical wound. Redivac drain will be used in this study.

Procedure: Subcutaneous drain
The drain will be inserted into subcutaneous layer of the surgical wound. Redivac drain will be used in this study.

Other: No drain

No drain will be inserted into the surgical wound in this arm.

Procedure: No drain
No drain will be inserted into patients allocated to this group

Outcome Measures

Primary Outcome Measures

  1. Rate of Surgical Site Infection (SSI) [Post operation day 3]

    The rate of SSI will be compared between the drain and no drain group

  2. Rate of Surgical Site Infection (SSI) [Post operation day 5]

    The rate of SSI will be compared between the drain and no drain group

  3. Rate of Surgical Site Infection (SSI) [Post operation day 7]

    The rate of SSI will be compared between the drain and no drain group

  4. Rate of Surgical Site Infection (SSI) [Post operation day 14]

    The rate of SSI will be compared between the drain and no drain group

  5. Rate of Surgical Site Infection (SSI) [Post operation day 30]

    The rate of SSI will be compared between the drain and no drain group

Secondary Outcome Measures

  1. Length of hospital stay [Post operation day 3]

    The length of hospital stay will be compared between drain and no drain group

  2. Length of hospital stay [Post operation day 5]

    The length of hospital stay will be compared between drain and no drain group

  3. Length of hospital stay [Post operation day 7]

    The length of hospital stay will be compared between drain and no drain group

  4. Length of hospital stay [Post operation day 14]

    The length of hospital stay will be compared between drain and no drain group

  5. Length of hospital stay [Post operation day 30]

    The length of hospital stay will be compared between drain and no drain group

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age equal or over 18 years old

  • Admitted to Queen Savang Vadhana Memorial Hospital

  • Receive abdominal surgery and were classified as class 3 or 4 wound

Exclusion Criteria:
  • Patients who undergo operation for ostomy

  • Patients who do not receive appropriate antibiotics

  • Patients who undergo operation before full recover of prior operation

  • Patients who undergo laparoscopic operation

  • Pregnant women

  • Patients who had history of prior radiation therapy at abdomen

  • Patient with immunocompromised status

  • Patient with chronic skin disease

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Queen Savang Vadhana Memorial Hospital, Thailand

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Queen Savang Vadhana Memorial Hospital, Thailand
ClinicalTrials.gov Identifier:
NCT06063629
Other Study ID Numbers:
  • 030/2565
First Posted:
Oct 2, 2023
Last Update Posted:
Oct 2, 2023
Last Verified:
Sep 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 2, 2023